Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors

AstraZeneca

Status: Completed

Conditions: Hypercholesterolaemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01257971

NIS-CHR-CRE-2010/1

Details and patient eligibility

About

This is a multi-centre non-interventional study of patients who are treated with any HMGCoA reductase inhibitor available in Croatia (rosuvastatin, simvastatin, atorvastatin and fluvastatin) for at least 6 months. All HMG-CoA reductase inhibitors must be prescribed in accordance with SmPCs approved in Croatia. Data collection for each patient will take place at a single visit. The investigator will complete a Case Report Form with the patient's demographics, the presence of the factors for high cardiovascular risk, current treatment, cholesterol values as well as with further treatment decision.

Enrollment: 1,868 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who have been treated with one HMG-CoA reductase inhibitor for at least 6 months without changing the dose for the last 4 weeks at least.
• All patients must sign Informed consent form.

Exclusion criteria

• Patients who have not signed the Informed consent form.
• Patients with contraindication for the treatment with HMG-CoA reductase inhibitors as per SmPC approved in Croatia.

Trial design

1,868 participants in 1 patient group

1

Description:

Patients with hypercholesterolaemia